Latest Tax Incentives News

Cleo Diagnostics has secured a $1.7 million R&D tax refund, strengthening its cash reserves to $5.75 million as it advances toward a pivotal US clinical trial and FDA submission for its ovarian cancer test.

Elixir Energy has raised approximately AUD 16.6 million through a two-tranche placement led by Omega Oil & Gas, aiming to fast-track its Taroom Trough gas projects and advance toward commercial production.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

Wide Open Agriculture has received a $586,624 tax rebate for its overseas research activities in Germany, supporting the commercialisation of its proprietary lupin protein products.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.

Elixir Energy has secured a specialized rig imported by Shell to drill the pivotal Lorelle-3 appraisal well in Queensland’s Taroom Trough, with operations set to begin in January 2026. This move aims to validate Elixir’s substantial gas resources adjacent to Shell’s acreage.

Janus Electric Holdings has updated its FY25 financials with audited figures, correcting prior R&D expense misstatements and recognizing an impairment on its Vaulta investment, resulting in a net loss of $8.9 million.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Spacetalk Ltd has secured an $877k R&D tax refund for FY2025, more than doubling last year’s amount, underscoring its strategic pivot to software and a 20% growth in recurring revenue.

Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.